NMTRC14: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Brief description of study

If you or your child have been diagnosed with neuroblastoma that is now in remission, you or your child may be qualified to participate in this study. The purpose of this research study is to evaluate the safety and tolerability of an investigational drug, Difluoromethylornithine (DFMO), for Neuroblastoma that is in remission.


Clinical Study Identifier: s17-01273
ClinicalTrials.gov Identifier: NCT02679144


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.